comprehensive -WSS

comprehensive

author：leisure time 2025-08-26 10:54:16 - browse：924

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Biotech lab space demand falls sharply

Wikipedia

knowledge

WSS

Glen Campbell's doctor discusses his public struggle with Alzheimer's

CDC advisers recommend seasonal use of Pfizer RSV shot

CDC advisers recommend seasonal use of Pfizer RSV shot

What Congress can do to address the rural doctor shortage

Venture capitalist Bob Kocher on the state of digital health

STAT Virtual Event: Putting AI to the Test

knowledge

comprehensive

entertainment

In Memoriam: Notable people who died in 2023

It's time to retire 'poor historian' from clinicians' vocabularies

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Arc Institute generative AI designs new CRISPR systems

Cancer drug shortages should be causing more outrage

Glen Campbell's doctor discusses his public struggle with Alzheimer's

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Helping hospitals and community health centers plan for resilience

Medicare details structure of new drug price negotiation program

Anxious about a speech? A startup wants you to pop a minty cardiac drug

leisure time

Intarcia’s device

Case highlights the risks of experimental stem cell therapy

EpiPen alternative approval delay highlights citizen petition issue

Hearing on Medicare drug price negotiation gets unusually heated

Changes to biosimilar regulatory framework must prioritize patients

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Wikipedia

knowledge

focus

hotspot